Novartis' plea for Glivec patent denied by Indian high court

04/1/2013 | Reuters

Western drugmakers suffered a major blow after the Indian Supreme Court rejected Novartis' petition for patent protection for its cancer treatment Glivec. The landmark ruling sets a reference point for other intellectual-property disputes in the country and is likely to affect many other drugmakers and their brand-name treatments, analysts say.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park